IFP Advisors’s Allogene Therapeutics ALLO Stock Holding History

IFP Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23K	Buy	593 +298	+101%	+$654	﹤0.01%	4435
2026 Q1	$720	Sell	295 -518	-64%	-$1.04K	﹤0.01%	4327
2025 Q4	$1.11K	Sell	813 -225	-22%	-$297	﹤0.01%	4039
2025 Q3	$1.29K	Buy	1,038 +1,007	+3,248%	+$1.2K	﹤0.01%	3849
2025 Q2	$35	Buy	+31	New	+$41	﹤0.01%	4820
2021 Q2	–	Sell	-3,258	Closed	-$92.9K	–	3051
2021 Q1	$115K	Hold	3,258	–	–	﹤0.01%	1106
2020 Q4	$82K	Hold	3,258	–	–	﹤0.01%	1221
2020 Q3	$123K	Hold	3,258	–	–	0.01%	896
2020 Q2	$136K	Hold	3,258	–	–	0.01%	803
2020 Q1	$67K	Hold	3,258	–	–	0.01%	990
2019 Q4	$87K	Hold	3,258	–	–	0.01%	1012
2019 Q3	$89K	Buy	+3,258	New	+$92.8K	0.01%	1115
2019 Q1	$115K	Buy	+4,033	New	+$117K	0.02%	643

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

IFP Advisors's ALLO Position: Q2 2026 in Review

IFP Advisors increased its Allogene Therapeutics (ALLO) stake by 101% in Q2 2026, buying an estimated $654 and bringing the position to 593 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #4435.

IFP Advisors first reported a position in ALLO in Q1 2019 and has held it in 13 quarters since. The position peaked at $136K in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

IFP Advisors held 593 shares of Allogene Therapeutics worth $1.23K as of Q2 2026.
IFP Advisors bought 298 Allogene Therapeutics shares in Q2 2026, an estimated $654.
Allogene Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4435 holding.
IFP Advisors first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 13 quarters since.
IFP Advisors's Allogene Therapeutics position peaked at $136K in Q2 2020.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.